WPD Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
WPD Pharmaceuticals has been growing earnings at an average annual rate of 70%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
70.0%
Earnings growth rate
70.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2021 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How WPD Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 21 | 0 | -5 | 4 | 2 |
| 30 Jun 21 | 0 | -5 | 4 | 2 |
| 31 Mar 21 | 0 | -6 | 6 | 1 |
| 31 Dec 20 | 0 | -8 | 7 | 0 |
| 30 Sep 20 | 0 | -16 | 8 | 0 |
| 30 Jun 20 | 0 | -16 | 7 | 0 |
| 31 Mar 20 | 0 | -14 | 5 | 0 |
| 31 Dec 19 | 0 | -12 | 3 | 0 |
Quality Earnings: 8SV1 is currently unprofitable.
Growing Profit Margin: 8SV1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 8SV1's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 8SV1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8SV1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 8SV1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.